Stock TRML TOURMALINE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
15.5 USD -1.15% Intraday chart for Tourmaline Bio, Inc. 0.00% -40.79%
04-25 Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI
04-25 Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jefferies Starts Coverage on Tourmaline Bio with Buy Rating, $41 Price Target
MT
Truist Starts Tourmaline Bio With Buy Rating, $43 Price Target
MT
Piper Sandler Initiates Coverage on Tourmaline Bio with Overweight Rating, $65 Price Target
MT
HC Wainwright Downgrades Talaris Therapeutics to Neutral From Buy
MT
Morgan Stanley Adjusts Price Target on Talaris Therapeutics to $3 From $6, Keeps Equalweight Rating
MT
HC Wainwright Adjusts Talaris Therapeutics' Price Target to $12 From $18, Maintains Buy Rating
MT
SVB Securities Lowers Talaris Therapeutics Price Target to $2 From $7, Maintains Market Perform Rating
MT
HC Wainwright Starts Talaris Therapeutics at Buy With $18 Price Target
MT
Morgan Stanley Cuts Price Target on Talaris Therapeutics to $6 From $8, Maintains Equalweight Rating
MT
Morgan Stanley Downgrades Talaris Therapeutics to Equalweight From Overweight; Price Target is $8
MT
SVB Securities Downgrades Talaris Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $21
MT
Morgan Stanley Adjusts Talaris Therapeutics' Price Target to $20 from $21, Keeps Overweight Rating
MT
Morgan Stanley Adjusts Talaris Therapeutics Price Target to $21 From $20, Maintains Overweight Rating
MT
TALARIS THERAPEUTICS : SVB Leerink Starts Talaris Therapeutics at Outperform With $21 Price Target
MT
TALARIS THERAPEUTICS : Evercore ISI Starts Talaris Therapeutics at Outperform With $35 Price Target
MT
TALARIS THERAPEUTICS : Morgan Stanley Starts Talaris Therapeutics at Overweight With $35 Price Target
MT
TALARIS THERAPEUTICS : Guggenheim Starts Talaris Therapeutics at Buy With $26 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRML Stock
  4. News Tourmaline Bio, Inc.
  5. Analyst Reco.